Open AccessA Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes
Author(s) -
Christine P. Limonte,
Erkka Valo,
Daniel Montemayor,
Farsad Afshinnia,
Tarunveer S. Ahluwalia,
Tina Costacou,
Manjula Darshi,
Carol Forsblom,
Andrew N. Hoofnagle,
PerHenrik Groop,
Rachel G. Miller,
Trevor J. Orchard,
Subramaniam Pennathur,
Peter Rossing,
Niina Sandholm,
Janet K. SnellBergeon,
Hongping Ye,
Jing Zhang,
Loki Natarajan,
Ian H. de Boer,
Kumar Sharma
Publication year - 2020
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000510830
Subject(s) - medicine , renal function , population , type 1 diabetes , diabetes mellitus , type 2 diabetes , biomarker , oncology , endocrinology , biology , environmental health , biochemistry
Background: Individuals with type 1 diabetes (T1D) demonstrate varied trajectories of estimated glomerular filtration rate (eGFR) decline. The molecular pathways underlying rapid eGFR decline in T1D are poorly understood, and individual-level risk of rapid eGFR decline is difficult to predict. Methods: We designed a case-control study with multiple exposure measurements nested within 4 well-characterized T1D cohorts (FinnDiane, Steno, EDC, and CACTI) to identify biomarkers associated with rapid eGFR decline. Here, we report the rationale for and design of these studies as well as results of models testing associations of clinical characteristics with rapid eGFR decline in the study population, upon which “omics” studies will be built. Cases ( n = 535) and controls ( n = 895) were defined as having an annual eGFR decline of ≥3 and <1 mL/min/1.73 m 2 , respectively. Associations of demographic and clinical variables with rapid eGFR decline were tested using logistic regression, and prediction was evaluated using area under the curve (AUC) statistics. Targeted metabolomics, lipidomics, and proteomics are being performed using high-resolution mass-spectrometry techniques. Results: At baseline, the mean age was 43 years, diabetes duration was 27 years, eGFR was 94 mL/min/1.73 m 2 , and 62% of participants were normoalbuminuric. Over 7.6-year median follow-up, the mean annual change in eGFR in cases and controls was −5.7 and 0.6 mL/min/1.73 m 2 , respectively. Younger age, longer diabetes duration, and higher baseline HbA1c, urine albumin-creatinine ratio, and eGFR were significantly associated with rapid eGFR decline. The cross-validated AUC for the predictive model incorporating these variables plus sex and mean arterial blood pressure was 0.74 (95% CI: 0.68–0.79; p < 0.001). Conclusion: Known risk factors provide moderate discrimination of rapid eGFR decline. Identification of blood and urine biomarkers associated with rapid eGFR decline in T1D using targeted omics strategies may provide insight into disease mechanisms and improve upon clinical predictive models using traditional risk factors.